HyprView

📍 Paris, France👥 6 employees💰 Last funded Dec 2025
Biotechnology Research
LinkedIn
HyprView addresses the critical limits of current predictive biomarkers in oncology, where relying solely on genes and proteins fails to accurately match patients to precision therapies. The core innovation is a proprietary and patented imaging platform combining advanced photonics and AI to achieve unmatched data quality for a better patient stratification. From raw biopsies, we capture massive amount of information and apply deep learning to this unique data set to build comprehensive biomarker signatures for predicting therapy response.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Portugal
1
France
1
Frequently asked questions
Who invested in HyprView?
HyprView has 2 investors on record on gritt.io.
When did HyprView last raise funding?
The most recent investment in HyprView recorded on gritt.io was in December 2025.
What industry is HyprView in?
HyprView operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is HyprView based?
HyprView is headquartered in Paris, France.